Nevertheless, it is known that the overall survival of women diagnosed with HR+/HER2+ is better when compared to triple negative breast cancers, since HR+/HER2+ tumors may respond to targeted therapies. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.